[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vitreoretinal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vitreoretinal-disease":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,61,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":42,"overallStatus":49,"whyStopped":4,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":4},"100615866","wide-field-octa-in-ocular-diseases-100615866",false,"NCT07298174","Wide Field OCTA in Ocular Diseases","Wide Field OCTA in Ocular Diseases: a Prospective Observational Study of the Clinical Impact of Wide Field OCTA in Ocular Disease.","WOOD-2025","Inclusion Criteria:\n\n* Age \\> 18 years\n* Both genders\n* Confirmed diagnosis of one of the above diseases\n* Age-related macular degeneration\n* Diabetic retinopathy\n* Myopia\n* Pachychoroid spectrum disease\n* Inherited retinal dystrophy\n* Uveitis\n* Dry eye\n* Visual acuity of at least 1\u002F20\n* Signed informed consent for the participation to the trial.\n\nExclusion Criteria:\n\n* Media opacities\n* Any other eye or systemic condition that may irreversibly impair the results of the study\n* Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment",true,"ALL","18 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function. Often, such diseases affect the noblest part of the retina, called macula. Many retinal diseases can be complicated by choroidal neovascularization which causes frequent bleeding and fluid leakage that accumulates in the subretinal and intraretinal spaces. Although the investigators know many details of each disease affecting the retina, very often the correct diagnostic framework can be complicated, given the presence of morphological elements common to the different pathologies. Similarly, predicting the effect of treatment and the patient's outcome is a constant challenge for the ophthalmologists. Most of the current research has been focused on the assessment of vascular alterations localized in the macula. However, growing evidence highlight the importance of peripheral vascular changes on the outcome of retinal diseases. These changes can be detected only be wide field OCT devices.\n\nOn the other hand, ocular inflammation and hyperemia represent major assessments in anterior segment disorders, such as dry eye disease. The current grading systems of ocular inflammation, redness and hyperemia are characterized by several limitations, thus making these evaluations still mainly confined to the subjective assessment performed by the ophthalmologist. However, the new generation OCT devices may include also an anterior segment module which can reconstruct anterior segment vessels, non-invasively, using the same technology described for retinal diseases.\n\nThe main goal of the study is to evaluate the diagnostic contribution of a new generation wide field OCTA device in ocular diseases, which has recently received CE marking. In particular, the investigators will evaluate this new generation device both in retinal and anterior segments diseases, testing for common points and differences with the standard of care non-invasive diagnostic devices. Secondary outcomes include the assessment of the correlation between the patient's visual function (visual acuity) and morphological changes (standard of care imaging assessment) highlighted by the wide field OCT device, with particular attention to microstructural differences between major ocular diseases and the possible development of non-invasive biomarkers, useful for the diagnosis and follow-up of such pathologies.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Age - Related Macular Degeneration (AMD)","Diabetic Macular Edema","Diabetic Retinopathy","Myopia","Inherited Retinal Disease","Stargardt Disease","Retinitis Pigmentosa (RP)","Best Disease","Geographic Atrophy","Macular Neovascularisation","Ocular Surface Disease","Central Serous Choroidopathy","Pachychoroid Disease","Uveitis","Vitreoretinal Disease","Retinal Vein Occlusion",[43,44,45,46,47,48],"wide-field octa","multimodal retinal imaging","quantitative imaging","retinal disease","macular disease","ocular surface disease","NOT_YET_RECRUITING","2025-12-22",{"date":52,"type":53},"2025-12-30","ACTUAL",{"date":55,"type":22},"2026-01",{"date":57,"type":22},"2028-05",{"name":59,"class":60},"IRCCS San Raffaele","OTHER",{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100538728","a-prospective-open-label-single-center-study-of-the-acusurgical-luca-system-for-treatment-of-vitreoretinal-diseases-100538728","NCT06294613","A Prospective, Open-label, Single-center, Study of the ACUSURGICAL Luca System for Treatment of Vitreoretinal Diseases","Inclusion Criteria:\n\n* Given written Informed Consent by subject,\n* Males or females aged 18 - 85 years, pseudophakic or aphakic,\n* Willing and able to comply with the schedule for follow-up visits,\n* Requiring vitrectomy under general anesthesia (conditions include vitreous hemorrhage treatment (with potential clinical conditions including diabetic retinopathy, vascular occlusion, adverse effect of anticoagulant therapy), macular pucker),\n* BCDVA \\\u003C7\u002F10,\n* Deemed fit for robotic surgery per surgeons' assessment, including ability to undergone general anesthesia,\n* Beneficiary of health insurance.\n\nExclusion Criteria:\n\n* Uncontrolled systemic disease that could increase the operative risk or confound the outcome (autoimmune disease, uncontrolled hypertension, lung and heart disease impairing respiratory function, or any other medical condition as deemed by the Clinical Investigator),\n* BMI (kg\u002Fm²) \\> 30,\n* Axial length \\\u003C22 or \\>26 mm per ocular biometry, inclusive,\n* Presence of clinically significant ocular inflammation or infection within 30 days of Preop Visit, such as CME, uveitis, etc.,\n* Ocular condition, that in the opinion of the Clinical Investigator, may predispose for future complications or confound visual acuity results, including profound amblyopia (\\\u003C1\u002F10) or strabismus,\n* Ocular condition presenting associated pathology likely to require additional surgical manipulation, such as known need for membrane peeling, or retinal neovacular formation to be cut,\n* Already vitrectomized on the study eye,\n* Presenting retinal detachment or retinal tear,\n* History of ocular traumatism; post-traumatic vitreous hemorrhage,\n* Corneal scar preventing clear visualization of fundus,\n* Any associated ocular pathology or ocular degenerative disorder that is uncontrolled such as glaucoma with clinical visual defect or IOP not controlled by medical treatment, uveitis, optic nerve damage,\n* Subjects without light perception,\n* Subject participating in other clinical studies,\n* Subject being dependent on the Sponsor or Clinical Investigator,\n* Pregnant or lactating women, based on self-declaration.","85 Years",{"count":69,"type":22},15,"INTERVENTIONAL",[72],"NA","Prospective, interventional, open-label, non-controlled, monocentric study in Belgium of Luca, of up to 15 evaluable subjects, undergoing vitreoretinal surgery to treat intravitreal hemorrhage and macular pucker.\n\nOnly one eye per subject can be enrolled.",[40],"RECRUITING","2025-01-28",{"date":78,"type":53},"2025-01-30",{"date":80,"type":53},"2024-02-08",{"date":82,"type":22},"2026-07",{"name":84,"class":85},"Acusurgical","INDUSTRY",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":18,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":86},"100549127","metabolomic-profile-of-vitreoretinal-diseases-an-nmr-based-approach-using-vitreous-100549127","NCT06429969","Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.","Nuclear Magnetic Resonance (NMR)-Based Metabolomic Characterisation of Vitreoretinal Diseases Using Vitreous Fluid","NMR","Inclusion Criteria:\n\n1. Confirmation of IMH diagnosis with concomitant need for PPV surgery;\n2. Confirmation of DR diagnosis with concomitant need for PPV surgery;\n3. Confirmation of RD diagnosis with concomitant need for PPV surgery;\n4. Confirmation of IMM diagnosis with concomitant need for PPV surgery;\n5. Confirmation of RVO diagnosis with concomitant need for PPV surgery.\n\nExclusion Criteria:\n\n1. Diagnosed vitreoretinal disease with no need for PPV surgery;\n2. Previous history of PPV surgery;\n3. Combination of other active ophthalmic diseases, such as acute conjunctivitis and uveitis;\n4. Combination of serious systemic diseases such as hypertension and diabetes mellitus.","40 Years","90 Years",{"count":98,"type":22},450,"The goal of this observational study was to learn about metabolomics profiles in vitreoretinal diseases by nuclear magnetic resonance (NMR)using vitreous fluid. The main question it aimed to answer was abnormal biomarkers for common retinal diseases such as idiopathic macular hole(IMH), diabetic retinopathy(DR) and retinal detachment(RD). Participants would not be subjected to any intervention and the investigators would only collect preoperative information and remaining vitreous samples. The investigators divided the participants into groups with appropriate disease names based on the disease diagnosis, such as IMH group, DR group, and RD group. The MH group was used as a control group, investigators compared other groups to see the metabolomic abnormalities.",[40],"2024-05-21",{"date":103,"type":53},"2024-05-28",{"date":105,"type":53},"2024-01-17",{"date":107,"type":22},"2027-12-31",{"name":109,"class":60},"Renmin Hospital of Wuhan University"]